Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6154

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
26 February 2024 - 25 March 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
22 November 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
23 October 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid- January 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
05 September 2023 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late-November 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-February 2024.
15 February 2023 Please note that belzutifan will not be included in the renal cell carcinoma pathways evaluation at this time. NICE and the company are continuing to liaise about scheduling for this topic and further participation in the pathway evaluations.
21 November 2022 Please note that the evaluation of belzutifan for previously treated advanced renal cell carcinoma will now be conducted via ID6186 considering multiple treatments for renal cell carcinoma.
13 October 2022 In progress. DHSC referral received
11 July 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual